- Report
- May 2026
- 138 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- May 2026
- 145 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 142 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 148 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 147 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 136 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 136 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 145 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- April 2026
- 148 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- March 2026
- 144 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- March 2026
- 141 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- February 2026
- 141 Pages
Global
From €2656EUR$2,999USD£2,275GBP
€3541EUR$3,999USD£3,034GBP
- Report
- May 2026
- 400 Pages
Global
From €4383EUR$4,949USD£3,755GBP
- Report
- April 2026
- 160 Pages
Global
From €2940EUR$3,320USD£2,519GBP
€3675EUR$4,150USD£3,149GBP
- Report
- November 2025
- 160 Pages
Global
From €2798EUR$3,160USD£2,398GBP
€3498EUR$3,950USD£2,997GBP
- Report
- October 2025
- 160 Pages
Global
From €2798EUR$3,160USD£2,398GBP
€3498EUR$3,950USD£2,997GBP
- Report
- October 2025
- 160 Pages
Global
From €2798EUR$3,160USD£2,398GBP
€3498EUR$3,950USD£2,997GBP
- Report
- May 2026
- 149 Pages
Global
From €3498EUR$3,950USD£2,997GBP
- Report
- May 2026
- 154 Pages
Global
From €3498EUR$3,950USD£2,997GBP
- Report
- May 2026
- 165 Pages
Global
From €3498EUR$3,950USD£2,997GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more